Immix Biopharma, Inc. (IMMX)
9.43
+0.14
(+1.51%)
USD |
NASDAQ |
Oct 09, 13:05
Immix Biopharma Shareholders Equity (Quarterly) : 228.92M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 228.92M |
| March 31, 2026 | 84.36M |
| December 31, 2025 | 93.80M |
| September 30, 2025 | 8.265M |
| June 30, 2025 | 4.653M |
| March 31, 2025 | 9.594M |
| December 31, 2024 | 13.25M |
| September 30, 2024 | 17.55M |
| June 30, 2024 | 23.89M |
| March 31, 2024 | 27.92M |
| Date | Value |
|---|---|
| December 31, 2023 | 16.41M |
| September 30, 2023 | 19.77M |
| June 30, 2023 | 13.23M |
| March 31, 2023 | 11.77M |
| December 31, 2022 | 13.16M |
| September 30, 2022 | 16.75M |
| June 30, 2022 | 18.11M |
| March 31, 2022 | 19.65M |
| December 31, 2021 | 17.99M |
| September 30, 2021 | -6.196M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Atossa Therapeutics, Inc. | 26.83M |
| ACADIA Pharmaceuticals, Inc. | 1.307B |
| Alnylam Pharmaceuticals, Inc. | 1.354B |
| Savara, Inc. | 143.66M |
| Vericel Corp. | 370.04M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 239.11M |
| Total Liabilities (Quarterly) | 10.19M |
| Debt to Equity Ratio | 0.0044 |
| Current Ratio | 25.13 |
| Net Debt Paydown Yield | 0.00% |